CRBP · Corbus Pharmaceuticals Holdings, Inc.

0001193125-26-233507

Summary

Corbus Pharmaceuticals appointed Nishant Saxena as Chief Business Officer and granted equity awards to new board member Brent Pfeiffenberger.

Key takeaways

Nishant Saxena appointed CBO with a $470,000 base salary and equity grants totaling 192,300 options and 58,300 RSUs.
Brent Pfeiffenberger received initial equity awards of 24,700 stock options and 7,500 RSUs in connection with board appointment.
Saxena's employment agreement includes non-compete (6 months) and severance provisions tied to change in control.

Full analysis

The appointments strengthen Corbus's leadership as it transitions to registrational-stage development for CRB-701 in head and neck squamous cell carcinoma. Saxena, a former Evercore managing director, brings corporate development and capital markets expertise, while Pfeiffenberger adds board-level oversight. The equity awards align compensation with long-term shareholder value and retain key talent.